Artes Biotechnology  GmbH  
HomeAbout ARTESTechnologiesOfferProductsContact   
  Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services
ARTES Biotechnology GmbH

Biotechnological Processes and Products for Today and Tomorrow
ARTES Biotechnology is a well established development partner for recombinant protein production. Several bio-pharmaceutical products and industrial enzymes have been successfully introduced worldwide in the market by our clients and licensees.

ARTES Biotechnology delivers safe, robust and cost efficient protein production based on microbial cell lines including yeast (Hansenula polymorpha, syn. Pichia angusta) and bacteria (E. coli).

Our unique virus like particle (VLP) platform is applied for development of safe and affordable vaccines.

ARTES´ proprietary technologies ensure freedom-to-operate and reliable, competitive production. WHO recommendation, international registration, FDA approval and GRAS certification are part of the track record achieved in our international collaborations.

Large scale manufacturing and full analytics in accordance with cGMP guidelines are warranted in collaboration with a network of industrial partners.


A wide range of processes and products is available in our portfolio for immediate technology transfer.


New cell lines and processes for your product of interest are developed specifically to meet your demands.

Artes Biotechnology GmbH | Contract R&D Services.

16.03.2015 ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expression systems announces a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health.
ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and very economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
“This collaboration is another milestone in expanding our vaccine development expertise”, Michael Piontek, managing director of ARTES stated. “We are more than confident that our technology platform is perfectly suited for the development of safe and cost efficient vaccines that are highly relevant for the veterinary market.”
“Partnering is a central part of our strategy. We are excited about this collaboration and the opportunity to develop more innovative vaccines for the animal health market,” says Rolf-Dieter Günther, Head of Global Business Development and Licensing Animal Health for Boehringer Ingelheim.


Top of Page
  Copyright by Artes Biotechnology GmbH 2013